Inventor
RAMAKRISHNAN BOOPATHY
US27 patents
⚠️ This page may combine multiple inventors who share the name “RAMAKRISHNAN BOOPATHY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
VISTERRA INC
21 patentsUS11136385B2Oct 5, 2021
Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody molecule
VISTERRA INC4 citations83
US10954296B2Mar 23, 2021
Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGA
VISTERRA INC4 citations83
US10385123B2Aug 20, 2019
Antibody molecules to a proliferation-inducing ligand (APRIL)
VISTERRA INC8 citations83
US10981982B2Apr 20, 2021
Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)
VISTERRA INC1 citations72
US10968270B2Apr 6, 2021
Antibody molecules to a proliferation-inducing ligand (APRIL)
VISTERRA INC3 citations72
US11912781B2Feb 27, 2024
Humanized complement 5A receptor 1 antibodies and methods of use thereof
VISTERRA INC1 citations71
US11168131B2Nov 9, 2021
Antibody molecule-drug conjugates and uses thereof
VISTERRA INC4 citations69
US12415865B2Sep 16, 2025
Antibody molecules to C5AR1 and uses thereof
VISTERRA INC0 citations61
US12187807B2Jan 7, 2025
Antibody molecules to C5AR1 and uses thereof
VISTERRA INC0 citations61
US12091451B2Sep 17, 2024
Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)
VISTERRA INC0 citations61
US11773179B2Oct 3, 2023
Antibody molecules to C5aR1 and uses thereof
VISTERRA INC0 citations61
US12338291B2Jun 24, 2025
Humanized antibody molecules to CD138 and uses thereof
VISTERRA INC0 citations60
US12264203B2Apr 1, 2025
Humanized complement 5a receptor 1 antibodies and methods of use thereof
VISTERRA INC0 citations60
US12227587B2Feb 18, 2025
Humanized complement 5A receptor 1 antibodies and methods of use thereof
VISTERRA INC0 citations60
US12297249B2May 13, 2025
Interleukin-2 agents and uses thereof
VISTERRA INC0 citations59
US12084484B2Sep 10, 2024
Interleukin-2 agents and uses thereof
VISTERRA INC0 citations59
US11945868B2Apr 2, 2024
Antibody molecules to CD138 and uses thereof
VISTERRA INC1 citations59
US11858980B2Jan 2, 2024
Engineered polypeptides and uses thereof
VISTERRA INC0 citations59
US12098178B2Sep 24, 2024
Methods of using interleukin-2 agents
VISTERRA INC0 citations54
US11890319B2Feb 6, 2024
Antibody molecule-drug conjugates and uses thereof
VISTERRA INC0 citations49
US11969476B2Apr 30, 2024
Antibody molecule-drug conjugates and uses thereof
VISTERRA INC0 citations46
QASBA PRADMAN K
3 patentsUS8512991B2Aug 20, 2013
Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use
QASBA PRADMAN K2 citations55
US9222080B2Dec 29, 2015
Alpha 1-3 N-galactosylstransferase with altered donor specificities, compositions and methods of use
QASBA PRADMAN K0 citations42
US8425901B2Apr 23, 2013
Alpha 1-3 N-galactosyltransferase with altered donor specificities
QASBA PRADMAN K0 citations42
US HEALTH
2 patentsUS9738726B2Aug 22, 2017
HER2-specific monoclonal antibodies and conjugates thereof
US HEALTH12 citations82
US7482133B2Jan 27, 2009
Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US HEALTH2 citations55